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Résumé en
anglais
OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH)
derivative, developed for once-weekly administration. This study aimed to evaluate
the safety of once-weekly somapacitan vs once-daily Norditropin. Local tolerability
and treatment satisfaction were also assessed.
DESIGN: 26-week randomized, controlled phase 3 safety and tolerability trial in six
countries (Nbib2382939).
METHODS: Male or female patients aged 18-79 years with adult GH deficiency
(AGHD), treated with once-daily GH for ≥6 months, were randomized to once-weekly
somapacitan ( = 61) or once-daily Norditropin ( = 31) administered subcutaneously by
pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth
factor I (IGF-I) standard deviation score (SDS) levels within the normal range, and
then administered at a fixed dose. Outcome measures were adverse events (AEs),
including injection site reactions; occurrence of anti-somapacitan/anti-GH antibodies
and change in treatment satisfaction, assessed using the Treatment Satisfaction
Questionnaire for Medication-9 (TSQM-9).
RESULTS: Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in
both groups. AEs were mostly mild or moderate and transient in nature. The most
common AEs were nasopharyngitis, headache and fatigue in both groups. More than
1500 somapacitan injections were administered and no clinically significant injection
site reactions were reported. No anti-somapacitan or anti-GH antibodies were
detected. The TSQM-9 score for convenience increased significantly more with
somapacitan vs Norditropin ( = 0.0171).
CONCLUSIONS: In this 26-week trial in patients with AGHD, somapacitan was well
tolerated and no safety issues were identified. Once-weekly somapacitan was
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